Next Article in Journal
Less Carcinogenic Chlorinated Estrogens Applicable to Hormone Replacement Therapy
Next Article in Special Issue
Immune Signaling Kinases in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)
Previous Article in Journal
Hypoxia and Hypoxia-Inducible Factor Signaling in Muscular Dystrophies: Cause and Consequences
Previous Article in Special Issue
T-Type Ca2+ Enhancer SAK3 Activates CaMKII and Proteasome Activities in Lewy Body Dementia Mice Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 13
10.3390/ijms22137219
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ginsenoside Re Protects against Serotonergic Behaviors Evoked by 2,5-Dimethoxy-4-iodo-amphetamine in Mice via Inhibition of PKCδ-Mediated Mitochondrial Dysfunction

by
Eun-Joo Shin
1,†,
Ji Hoon Jeong
2,†,
Bao-Trong Nguyen
1,
Naveen Sharma
1,2,
Seung-Yeol Nah
3,
Yoon Hee Chung
4,
Yi Lee
5,
Jae Kyung Byun
6,
Toshitaka Nabeshima
7,
Sung Kwon Ko
8,* and
Hyoung-Chun Kim
1,*
1
Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Chunchon 24341, Korea
2
Department of Global Innovative Drugs, Graduate School of Chung-Ang University, College of Medicine, Chung-Ang University, Seoul 06974, Korea
3
Ginsentology Research Laboratory, Department of Physiology, College of Veterinary Medicine and Bio/Molecular Informatics Center, Konkuk University, Seoul 05029, Korea
4
Department of Anatomy, College of Medicine, Chung-Ang University, Seoul 06974, Korea
5
Department of Industrial Plant Science & Technology, Chungbuk National University, Chungju 28644, Korea
6
Korea Society of Forest Environmental Research, Namyanju 12106, Korea
7
Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Science, Toyoake 470-1192, Japan
8
Department of Oriental Medical Food and Nutrition, Semyung University, Jecheon 27136, Korea
*
Authors to whom correspondence should be addressed.
†
First two authors equally contributed to this work.
Int. J. Mol. Sci. 2021, 22(13), 7219; https://doi.org/10.3390/ijms22137219
Submission received: 13 May 2021 / Revised: 26 June 2021 / Accepted: 29 June 2021 / Published: 5 July 2021
(This article belongs to the Special Issue Protein Kinases and Neurodegenerative Diseases)
Browse Figures
Versions Notes

Abstract

:
It has been recognized that serotonin 2A receptor (5-HT2A) agonist 2,5-dimethoxy-4-iodo-amphetamine (DOI) impairs serotonergic homeostasis. However, the mechanism of DOI-induced serotonergic behaviors remains to be explored. Moreover, little is known about therapeutic interventions against serotonin syndrome, although evidence suggests that ginseng might possess modulating effects on the serotonin system. As ginsenoside Re (GRe) is well-known as a novel antioxidant in the nervous system, we investigated whether GRe modulates 5-HT2A receptor agonist DOI-induced serotonin impairments. We proposed that protein kinase Cδ (PKCδ) mediates serotonergic impairments. Treatment with GRe or 5-HT2A receptor antagonist MDL11939 significantly attenuated DOI-induced serotonergic behaviors (i.e., overall serotonergic syndrome behaviors, head twitch response, hyperthermia) by inhibiting mitochondrial translocation of PKCδ, reducing mitochondrial glutathione peroxidase activity, mitochondrial dysfunction, and mitochondrial oxidative stress in wild-type mice. These attenuations were in line with those observed upon PKCδ inhibition (i.e., pharmacologic inhibitor rottlerin or PKCδ knockout mice). Furthermore, GRe was not further implicated in attenuation mediated by PKCδ knockout in mice. Our results suggest that PKCδ is a therapeutic target for GRe against serotonergic behaviors induced by DOI.

Graphical Abstract

1. Introduction

Ginseng (Panax ginseng) is a naturally occurring herb. Commercially available ginseng formulations are mainly extracted from the roots of ginseng plants [1]. Ginsenosides, a form of triterpene glycosides (saponins), are the major bioactive ingredients in ginseng. Importantly, it has been demonstrated that ginsenosides enhance brain function via antioxidative and antineuroinflammatory activities. In addition, they slow down or attenuate numerous neurodegenerative and psychiatric disorders. There are approximately 150 ginsenosides, and among them, 40 have been found in Panax ginseng per se [2,3]. In particular, ginsenoside Re (GRe) is the main ginsenoside that has shown potential neuroprotective activities [4]. Although mostly the root of the ginseng plant has been used in herbal medicine, earlier studies have reported that the main bioactive component of ginseng (i.e., GRe) is more abundantly present in berries, flower buds, and leaves than in the roots [4,5,6,7,8], indicating the important pharmacoeconomical intervention of GRe for developing naturally occurring drug resources. Therefore, in our previous studies, we have investigated the neuropsychoprotective activities of GRe [9,10,11,12,13].
Serotonin syndrome is a severe hazardous condition that can be life-threatening [14], and the syndrome includes altered mental status, autonomic responses, and the triad of motor symptoms [15,16]. Excessive serotonin release and consequent overactivation of central and peripheral serotonin receptors are known to cause serotonin syndrome [14]. For instance, abuse of serotonergic compounds, such as methylenedioxymethamphetamine (MDMA) [17,18,19,20,21,22], 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) [23], and psilocybin [24], or dissociative drugs, such as dextromethorphan [25,26,27,28], has been reported to provoke serotonin syndrome in humans. Indeed, it has been reported that frequent usage of antidepressants, such as monoamine oxidase (MAO) inhibitors and selective serotonin reuptake inhibitors (SSRIs), enhances the risk of serotonin syndrome [14,29]. Therefore, the fact that sustained exposure to antidepressant drugs presents a potential for inducing serotonin syndrome is of concern.
For example, fluoxetine, an SSRI, has various effects on energy metabolism in the hepatocellular mitochondria of rats, and it is potentially toxic at high doses [30]. It affects apoptosis by increasing the voltage sensitivity of the mitochondrial voltage-dependent anion channel [31]. Fluoxetine induces the inhibition of oxidative phosphorylation and decreases mitochondrial ATP synthase activity in the rat brain [32]. Exposure to norfluoxetine, an active metabolite of fluoxetine, reduces the membrane potential and activity of mitochondrial complexes and leads to apoptotic changes [33]. However, it is unclear whether mitochondrial dysfunction is involved in serotonin syndrome behaviors.
Among serotonin receptors, post-synaptic 5-HT1A and 5-HT2A receptors have been suggested to be importantly involved in serotonin syndrome [14,34]. Consistently, it has been reported that the specific 5-HT1A receptor agonist 8-OH-DPAT or the specific 5-HT2A receptor agonist (4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide TCB-2 induces serotonin syndrome behavior in mice [35,36,37]. In most cells and tissues, 5-HT receptors activate phospholipase C, which causes stimulation of protein kinase C (PKC) [38]. Among PKC isozymes, PKCδ is mainly involved in several cellular transduction pathways coupled with oxidative stress, inflammation, and cell death [39,40,41,42,43,44,45]. We [13,41,42,43,44,45,46,47,48,49] and others [50,51,52,53] have suggested that PKC is important for neuropsychotoxicity induced by amphetamine and its analogues. In particular, the PKCδ gene is a crucial target for generating serotonergic behaviors [35,54].
We have recently filed a patent (patent number KR 1-1-2020-1158807-40: The pharmaceutical composition for the prevention and treatment of serotonin syndrome behaviors). In this study, we observed that protopananxatriol saponins (PPT) blocked serotonergic behaviors in mice and that the GRe in PPT played a major role in attenuating against serotonin syndrome behaviors. Thus, in the present study, we attempted to extend our knowledge of the GRe-mediated pharmacological mechanism against the serotonergic behaviors induced by 2,5-dimethoxy-4-iodo-amphetamine (DOI), an amphetamine analog and a 5-HT2A receptor agonist. We investigated the following: (1) whether DOI-mediated 5-HT2A receptor stimulation induces mitochondrial dysfunction and the consequent oxidative burden; (2) whether PKCδ activation is involved in DOI-induced serotonergic changes, mitochondrial burden, and serotonergic behaviors using pharmacological and genetic inhibition of PKCδ; (3) whether GRe affects DOI-induced neuronal and behavioral changes; and (4) whether GRe modulates its effects by affecting PKCδ activation and consequent changes after DOI treatment. Since our recent studies have showed that the serotonergic impairment in the hypothalamus is much more pronounced than in the hippocampus or in the prefrontal cortex in several serotonin syndrome models [38,39,40], we have focused on the hypothalamic changes in the present study. We observed that GRe attenuated DOI-induced serotonin syndrome behaviors by inhibiting mitochondrial translocation of PKCδ, mitochondrial dysfunction, and mitochondrial oxidative damage, and impaired enzymatic antioxidant systems in the hypothalami of mice. Consistently, PKCδ knockout (PKCδ KO) attenuated against these neurobehavioral impairments caused by DOI in mice.

2. Results

2.1. Effect of GRe, Rottlerin, or MDL11939 (MDL) on the Mitochondrial Translocation of PKCδ Induced by DOI in the Wild-Type Mice

We recently demonstrated that hypothalamic PKCδ levels might play a critical role in inducing serotonin behaviors [35,54,55]. As shown in Figure 1 of the experimental design, we investigated whether GRe, the PKCδ inhibitor rottlerin, or the 5-HT2A receptor antagonist MDL affects the mitochondrial translocation of PKCδ induced by the 5-HT2A agonist DOI. As shown in Figure 2, DOI treatment significantly increased cytosolic PKCδ (p < 0.05 vs. saline/saline; Figure 2A) and mitochondrial PKCδ (p < 0.01 vs. saline/saline; Figure 2B) in wild-type mice. The effect of DOI seemed more evident in the mitochondrial fraction than the cytosolic fraction. This increase was significantly inhibited (p < 0.01 vs. saline/DOI) by GRe, rottlerin, or MDL, and the inhibition by GRe or MDL paralleled that by rottlerin (Figure 2B).

2.2. Effect of GRe or MDL11939 (MDL) on the Alterations in Mitochondrial Membrane Potential and Intra-Mitochondrial Ca2+ Level Elicited by DOI in the Wild-Type and PKCδ KO Mice

Earlier reports have indicated that DOI facilitated mitochondrial dysfunction [56]. We [10,12,13,57] and other researchers [58,59,60] have demonstrated that GRe attenuates mitochondrial dysfunction induced by neurotoxic insults. In addition, we have also reported that GRe attenuates mitochondrial dysfunction induced by dopaminergic insult via genetic and pharmacological inhibition of PKCδ [12,13]. Consistently, we observed here that DOI remarkably augmented the mitochondrial translocation of PKCδ (Figure 2B). Thus, we investigated whether GRe or PKCδ inhibition modulates the mitochondrial membrane potential and intramitochondrial Ca2+ levels induced by DOI. In addition, we examined the effect of 5-HT2A antagonism in our experimental conditions.
As shown in Figure 3A, DOI caused a significant decrease (p < 0.05 vs. saline/saline) in the mitochondrial membrane potential in the wild-type mice, whereas genetic depletion of PKCδ significantly attenuated (p < 0.05 vs. saline/DOI/wild-type) the decrease caused by DOI. Treatment with GRe, rottlerin, or MDL significantly inhibited (p < 0.05 vs. saline/DOI) DOI-induced decrease in the mitochondrial membrane potential in wild-type mice. However, neither GRe nor MDL affected PKCδ KO-mediated attenuation (Figure 3A).
As shown in Figure 3B, DOI significantly increased (p < 0.05 vs. saline/saline) intra-mitochondrial Ca2+ accumulation, this increase was significantly alleviated (p < 0.05 vs. saline/DOI) by GRe, rottlerin, or MDL in the wild-type mice. PKCδ KO also significantly attenuated (p < 0.05 vs. saline/DOI/wild-type) the DOI-induced increase in intra-mitochondrial Ca2+ levels in mice. However, neither GRe nor MDL significantly altered the PKCδ KO-mediated attenuation (Figure 3B).

2.3. Effect of GRe or MDL11939 (MDL) on the Alterations in the Mitochondrial Complex I and Complex II Activities Caused by DOI in Wild-Type and PKCδ KO Mice

DOI treatment significantly decreased complex I (p < 0.01 vs. saline/saline; Figure 4A) and complex II (p < 0.05 vs. saline/saline; Figure 4B) activities in the wild-type mice. These effects were significantly attenuated (p < 0.05 vs. saline/DOI/wild-type) by PKCδ KO in mice. Treatment with GRe, PKCδ inhibitor rottlerin, or MDL resulted in a significant attenuation (p < 0.05 vs. saline/DOI) of the DOI-induced decrease in complex I activity in the wild-type mice. GRe, rottlerin, or MDL appeared to attenuate this effect without reaching statistical significance. In addition, GRe or MDL did not significantly alter PKCδ KO-mediated potentials against mitochondrial complex I and II activities caused by DOI (Figure 4).

2.4. Effect of GRe or MDL11939 (MDL) on DOI-Induced Oxidative Stress in the Mitochondrial and Cytosolic Fractions of the Hypothalamus of Wild-Type and PKCδ KO Mice

We have recently demonstrated that 5-HT receptors require PKCδ to induce serotonergic behaviors and that PKCδ is an important factor for the harmful oxidant generation [35,54]. However, it remains to be elucidated whether the mitochondrial oxidative burden is involved in serotonergic behaviors. In this study, we found that DOI-induced oxidative stress appeared to be more evident in the mitochondrial fraction than in the cytosolic fraction, suggesting that mitochondria are more susceptible to DOI insult than cytosol. As shown in Figure 5, oxidative parameters (reactive oxygen species (ROS) formation, 4-hydroxynonenal (HNE), and protein carbonyl) in the mitochondrial and cytosolic fractions were significantly increased (cytosolic level of ROS, HNE, or protein carbonyl: p < 0.05 vs. saline/saline; mitochondrial level of ROS, HNE, or protein carbonyl: p < 0.01 vs. saline/saline) 1 h post-DOI treatment in wild-type mice.
DOI-induced increases in oxidative parameters were significantly attenuated by PKCδ KO in mice (cytosolic ROS, HNE, or protein carbonyl: p < 0.05 vs. saline/DOI wild-type; mitochondrial ROS, HNE, or protein carbonyl: p < 0.01 vs. saline/DOI/wild-type). GRe, rottlerin, or MDL significantly inhibited DOI-induced oxidative damage (cytosolic ROS, HNE, or protein carbonyl: p < 0.05 vs. saline/DOI; mitochondrial ROS, HNE, or protein carbonyl: p < 0.01 vs. saline/DOI) in either fraction of wild-type mice. However, in the presence of DOI, GRe or MDL did not significantly affect antioxidant activity afforded by PKCδ KO in mice (Figure 5).

2.5. Effect of GRe or MDL11939 (MDL) on Changes in the Mitochondrial and Cytosolic Activities of Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) Induced by DOI in Wild-Type and PKCδ KO Mice

It has been well-recognized that enzymatic antioxidants such as SODs, catalase, and peroxidases (i.e., GPx) are oxyradical scavengers; SOD catalyzes the dismutation of O2 (superoxide anion) to produce hydrogen peroxide (H2O2), and then catalase or GPx might catalyze the reduction of H2O2 to water. However, it is also apparent that in most eukaryotic cells, catalase is restricted to isolated compartments such as peroxisomes [61,62,63]; in particular, SOD and peroxidases (mainly GPx) are located in the cytoplasm and mitochondria of the cells [63,64,65,66]. Here, we asked whether GRe or genetic/pharmacological inhibition of PKCδ or MDL modulates SOD and GPx activities induced by DOI.
As shown in Figure 6, DOI significantly increased cytosolic SOD (SOD-1) (p < 0.05 vs. saline/saline) and mitochondrial SOD (SOD-2) activities (p < 0.01 vs. saline/saline) 60 min post-treatment in wild-type mice (Figure 6A,B). At that time, cytosolic and mitochondrial GPx activities were significantly decreased (cytosolic and mitochondrial fractions, p < 0.05 and p < 0.01 vs. saline/saline, respectively) in the presence of DOI in wild-type mice (Figure 6C,D).
GRe, rottlerin, or MDL significantly inhibited DOI-induced increases in cytosolic SOD-1 (DOI plus GRe, rottlerin, or MDL: p < 0.05 vs. saline/DOI) and mitochondrial SOD-2 (DOI plus GRe, rottlerin, or MDL: p < 0.01 vs. saline/DOI) activities (Figure 6A,B). Consistently, either one significantly attenuated decreases in cytosolic (DOI plus GRe, rottlerin, or MDL: p < 0.05 vs. saline/DOI) and mitochondrial (DOI plus GRe, rottlerin, or MDL: p < 0.01 vs. saline/DOI) GPx activities from DOI insult in wild-type mice (Figure 6C,D). We observed that mitochondrial enzymatic antioxidants appeared to be more susceptible to DOI burden than cytosolic enzymatic antioxidants. Efficacy of GRe, rottlerin, or MDL appeared to be selective in the mitochondrial fraction (>cytosolic fraction).
PKCδ KO also significantly attenuated DOI-induced changes in SOD-1 (p < 0.05 vs. saline/DOI/wild-type), SOD-2 (p < 0.01 vs. saline/DOI/wild-type), cytosolic GPx (p < 0.05 vs. saline/DOI/wild-type), and mitochondrial GPx (p < 0.01 vs. saline/DOI/wild-type) activities in mice. However, neither GRe nor MDL altered PKCδ KO-mediated attenuation of DOI-induced deregulation of cytosolic and mitochondrial SOD and GPx activities in mice (Figure 6A–D), suggesting that PKCδ is a critical target of antioxidant potential exhibited by GRe or MDL.

2.6. Effect of GRe or MDL11939 (MDL) against Serotonergic Behaaviors, Head Twitch Response, and Hyperthermia Caused by DOI in Wild-Type and PKCΔ KO Mice

Treatment with DOI resulted in significant hyperthermia, complex serotonergic behaviors (i.e., hind limb abduction, forepaw treading, straub tail, low body posture, lateral head weaving, and tremor; Supplementary Figure S2), and head twitch response in wild-type mice. PKCδ KO significantly attenuated DOI-induced overall serotonergic behavioral scores (12 min and 30 min post-DOI administration: p < 0.05 vs. DOI/wild-type; 18 min and 24 min post-DOI administration: p < 0.01 vs. DOI/wild-type) and head twitch response number (6 min, 12 min, 18 min, and 42 min post-DOI administration: p < 0.05 vs. DOI/wild-type; 24 min, 30 min, and 36 min post-DOI administration: p < 0.01 vs. DOI/wild-type), and hyperthermia (30 min, 45 min, 60 min, 75 min, 90 min, and 105 min post-DOI administration: p < 0.05 vs. DOI/wild-type) (Figure 7A,C,E).
Because DOI-induced serotonergic behavioral scores and head twitch response were more prominent in the first 30 min than in the second 30 min post-treatment, the effects of GRe, rottlerin, or MDL on the alterations in serotonergic behavioral score and head twitch response were evaluated during the first 30 min. In addition, the effect of GRe, rottlerin, or MDL on hyperthermia was examined 60 min post-DOI administration because hyperthermia was most evident at that time.
As shown in Figure 7B,D,F, GRe, rottlerin, or MDL significantly alleviated the overall serotoninergic behavioral score (p < 0.05 vs. saline/DOI), head twitch response (p < 0.05 vs. saline/DOI), and hyperthermia (p < 0.05 vs. saline/DOI) induced by DOI in wild-type mice. Consistently, PKCδ KO significantly mitigated the overall serotonergic behavioral score (p < 0.05 vs. saline/DOI/wild-type), head twitch response (p < 0.05 vs. saline/DOI/wild-type), and hyperthermia (p < 0.05 vs. saline/DOI/wild-type) in mice. The effects of PKCδ KO were comparable to those of rottlerin. In addition, neither GRe nor MDL had significant additional effects on PKCδ KO-mediated attenuation of the DOI-induced behavioral toxicity in mice.

3. Discussion

It is known that PKC is a critical molecular factor in the regulation of 5-HT receptors [67,68]. The 5-HT2 receptor family is related to the phosphorylation of PKC isozymes [69]. Moreover, PKC modulation is required for the internalization of 5-HT2A receptor [70,71]. There is evidence that 5-HT1A and 5-HT2A receptors are mainly responsible for developing serotonin syndrome [35,54,55,72]. Other studies also have provided the insight that the 5-HT2A receptor is closely associated with serotonergic behavioral responses [13,73].
We recently demonstrated that PKCδ might mediate serotonergic syndrome behaviors [35,54,55]. We also indicated that the neuroprotective effects mediated by ginsenoside are due to their antioxidant activity, mainly by alleviating synaptosomal/mitochondrial oxidative stress and mitochondrial dysfunction [10,12,13,42,74]. Similarly, the observations of the present study show that DOI-induced serotonergic behaviors are elicited mainly by mitochondrial oxidative stress, impaired enzymatic antioxidant system (i.e., reduced mitochondrial activity of GPx), mitochondrial translocation of PKCδ, decreases in mitochondrial transmembrane potential and mitochondrial complex (I > II) activity, and increased level of intra-mitochondrial Ca2+; GRe or 5-HT2A receptor antagonist MDL inhibits these morbid scenarios by inhibiting PKCδ.
Mitochondria are susceptible to oxidant, pro-inflammatory, and pro-apoptotic effects [75,76]. It is well-known that mitochondrial disturbances, such as alterations in the mitochondrial transmembrane potential, generate oxidative stress [76,77]. In addition, in vitro study in SH-SY5Y cells revealed that PKCδ might be responsible for the increased mitochondrial oxidative stress [78]. Moreover, our previous studies suggested that GRe exhibited protective effects against dopaminergic toxicity caused by methamphetamine, an amphetamine analog, via PKCδ-dependent mitochondrial oxidative stress and mitochondrial GPx activity in vitro/in vivo [12,13], indicating that mitochondria might be an intracellular target of GRe.
In this study, DOI treatment caused a constant and significant increase in SOD activity (mitochondria > cytosol) in the hypothalamus of wild-type mice, whereas it did not implicate a simultaneous increase in GPx activity, particularly in the mitochondrial fraction. Increased SOD activity may increase H2O2 accumulation, facilitate Fenton reaction, and result in irreversible cellular oxidative damage caused by lipid peroxidation (HNE)/protein oxidation/ROS [66]. Our observation of increased oxidative parameters indicates that GPx activity mainly modifies these endpoints rather than SOD. Furthermore, significant elevation of SOD-1 and SOD-2 activity in wild-type mice could be considered by the increased superoxide anion production during the oxidative insult caused by DOI. Thus, it is speculated that PKCδ inhibition or GRe-mediated GPx induction may be accountable for dropping H2O2 levels. Interestingly, as PKCδ is a well-known redox-sensitive kinase [79], oxidative stress has been shown to upregulate PKCδ activity and facilitate its mitochondrial translocation [43]. Upon mitochondrial translocation, PKCδ induces mitochondrial dysfunction and concurrent oxidative stress, as mentioned above. Thus, PKCδ can be an important mediator of positive feedback amplifiers between oxidative stress and mitochondrial dysfunction [43]. Considering our previous reports [35,54,55] and the present results showing that PKCδ plays a critical role in inducing serotonergic behaviors mediated by 5-HT1A or 5-HT2A receptors, it is suggested that DOI-induced oxidative stress contributes to the induction of serotonergic behaviors, and that GRe-mediated antioxidant potential is important for preventing DOI-induced serotonergic behaviors.
Handy et al. (2009) proposed that mitochondrial functions were regulated by GPx-1 to modulate redox-dependent cellular responses [80]. Moreover, GPx-1 KO increased mitochondrial oxidative stress in association with loss of mitochondrial energy production [81]. It is important to note that the GRe-mediated protective potential with the recovery of mitochondrial function requires inhibition of PKCδ. It is also plausible that GRe protects against DOI-induced mitochondrial impairment through the induction of GPx activity by inhibiting PKCδ. Hence, preservation of mitochondrial transmembrane potential by GRe or inhibition of PKCδ may be critical for the restoration of mitochondrial function.
We observed here that DOI, as a 5-HT2A agonist and an amphetamine analog, facilitated intramitochodrial Ca2+ accumulation, which further potentiated mitochondrial oxidative stress and also impaired mitochondrial transmembrane potential. Increased intracellular Ca2+ promoted the intramitochondrial Ca2+ accumulation when Ca2+ influx was more than total Ca2+ efflux [82]. This excessive mitochondrial Ca2+ may cause uncoupling of mitochondrial electron transport and eventually lead to oxidative damage. We speculate that GRe might attenuate Ca2+ influx via inhibition of the mitochondrial translocation of PKCδ, reflecting that GRe primarily restores mitochondrial function.
The effect of DOI on hypothalamic serotonin release has not been well understood. However, previous studies have shown that systemic administration of DOI decreases the extracellular serotonin release [83,84,85], while intra-prefrontal cortical infusion of DOI increases the extracellular serotonin release [86,87] in the prefrontal cortex. Therefore, it remains to be elucidated whether systemic or intrahypothalamic DOI administration significantly affects the serotonin release in the hypothalamus.
5-HT2A receptor-induced serotonergic burden was particularly specific in the hypothalamus [55,88,89]. Consistently, DOI-induced increased expression of c-Fos, a redox-sensitive factor, in the hypothalamus [90], was attenuated by 5-HT2A antagonist (i.e., MDL100907) [90]. Moreover, immunocytochemical and pharmacological data indicates that DOI principally activates 5-HT2A receptors [91], reflecting the importance of modulation of hypothalamic 5-HT2A receptor. We found that serotonergic behaviors triggered by 5-HT1A receptors paralleled those by 5-HT2A receptors [35,54]. However, either one played an opposite role in thermoregulation [92]; for example, activation of 5-HT1A causes hypothermia [35], whereas the stimulation of 5-HT2A receptors activates a hyperthermic response [29,93]. This phenomenon remains to be explored further.
Importantly, serotonin syndrome and hyperthermia can be modulated by therapeutic intervention of the 5-HT2A receptor antagonist, cyproheptadine, and ketanserin [14,29]. In addition, it has been reported that head twitch response is specifically mediated by the 5-HT2A receptor [94,95], and this effect is alleviated by the antagonism of 5-HT2A receptor [36]. Furthermore, in addition to traditional serotonergic behaviors, DOI also induced head twitch response in wild-type mice. Consistently, antagonism of 5-HT2A receptor (i.e., MDL) ameliorated serotonergic impairments, suggesting that 5-HT2A receptors specifically mediate DOI-induced serotonergic impairments. Among different serotonin receptors, 5-HT2A may be associated with complex behaviors [82]. Earlier studies suggested that head twitch response in mice represented a sort of hallucinogenic behavior [95,96], since hallucinogenic agents induce head twitch response in rodents. Thus, DOI is a frequently used pharmacological tool in the head twitch response studies of hallucinogens. Interestingly, mice lacking 5-HT2A receptors do not show a head twitch response to DOI. In contrast, restoration of cortical neuronal 5-HT2A receptors reinstates the DOI potential for inducing head twitch response in the 5-HT2A receptor KO mice [97], reflecting the prerequisite role of 5-HT2A receptors in inducing head twitch response.
In the current study, GRe or rottlerin, or MDL itself without DOI, did not induce significant behavioral or thermal changes (Supplementary Figure S3). Although we did not further examine their effect on the mitochondrial and antioxidant/prooxidant parameters in the absence of DOI in the present study, we have previously reported that GRe or rottlerin alone did not significantly affect the mitochondrial function, mitochondrial/cytosolic antioxidant defense system, or oxidative burden in various brain regions, including the striatum [13,41,46], prefrontal cortex [10], and hippocampus [42]. Nevertheless, the possibility that GRe, rottlerin, or MDL per se exerts its own effect on mitochondrial/cytosolic regulation cannot be ruled out, and it remains to be determined.
Our findings indicated that GRe attenuated the DOI-induced serotonergic impairments via the recovery from mitochondrial stress by PKCδ inhibition (genetic or pharmacological) in mice. Because GRe or MDL did alter PKCδ KO-mediated protective potentials in mice, it is plausible that PKCδ may be a mechanistic target for DOI-elicited 5-HT2A receptor activation.
In conclusion, our results suggest that PKCδ activation followed by mitochondrial burden might contribute to the serotonergic behaviors induced by DOI, and that the GRe-mediated protective potential regulated by PKCδ inhibition may lead to a novel therapeutic intervention against serotonergic behaviors.

4. Materials and Methods

4.1. Preparation of GRe

Mountain-cultivated ginseng (MCG; Panax ginseng) was purchased from Pyungchang, Kangwon Province, Republic of Korea, in August 2014. Dried MCG (5 kg) was extracted with 95% ethyl alcohol for 4 h at 78 °C, followed by concentration in vacuum. Ethyl alcohol extract 1320 g was dissolved in 1500 mL of water and extracted with diethyl ether (1500 mL). The water fraction was then evaporated. The water fraction (1214 g) was subjected to column chromatography over Diaion (5 kg) and eluted sequentially with H2O, 30% MeOH, 50% MeOH, 70% MeOH, and 100% MeOH. The 30% MeOH fraction (12.5 g) was chromatographed on ODS (C-18) gel (1 kg) with eluting solvents of 50% MeOH to give four subfractions (F1–F4). The F3 fraction (3.7 g) was further subjected to silica gel column chromatography (500 g, CHCl3: MeOH: H2O = 70: 30: 4 v/v) to produce GRe (650 mg) [98].

4.2. Animals

All experiments in this study, including the treatment of animals, were performed according to the National Institutes of Health (NIH) Guide for the Humane Care and Use of Laboratory Animals (NIH Publication No. 85–23, 1985; grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf; August 2019). All experiments were performed under the Institute for Laboratory Research (ILAR) Guidelines for the Care and Use of Laboratory Animals. Mice were caged in a room maintained at 22 ± 0.5 °C with 12:12 h light/dark cycle and fed ad libitum. All mice were allowed to adapt to the laboratory conditions for at least 2 weeks before the experiments. A breeding pair of PKCδ (±) mice (C57BL/6J background) was gifted by Dr. K. I. Nakayama (Dept. of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan) [99]. These mice were further bred into the C57BL/6J background for six generations. Male C57BL/6J background mice were used as wild-type mice in our experiments. DNA was obtained from the tails of mice for the genotyping of wild-type and PKCδ KO mice. Genotyping primers for polymerase chain reaction (PCR) were as follows: 5′-GGAAGAATAAGAAACTGCATCACC-3′ and 5′-GAAGGAGCCAGAACCGAAAG-3′ for endogenous detection, and 5′-GGAAGAATAAGAAA CTGCATCACC-3′ and 5′-TGGGGTGGGATTAG ATAAATG-3′ for mutant detection (Bioneer Corporation, Daejeon, Korea).

4.3. Drug Treatment

GRe, DOI (Sigma-Aldrich, St. Louis, MO, USA), and MDL11,939 (MDL; Sigma-Aldrich), a 5-HT2A receptor antagonist, were dissolved in sterile saline immediately before use. The PKCδ inhibitor, rottlerin (Biomol Research Laboratories Inc., Plymouth, PA, USA), was dissolved in dimethyl sulfoxide as a stock solution and stored at −20 °C. Rottlerin was further diluted in sterile saline at a concentration of 1 µg/μL immediately before use.
In the first experiment, male PKCδ KO and wild-type mice, weighing approximately 23 ± 2 g, received a single dose of DOI (2.5 mg/kg, i.p.) or saline. Temporal behavioral patterns and changes in rectal temperature were evaluated for 1 and 2 h, respectively. The application of DOI was based on previous studies [100,101]. In the second experiment, male PKCδ KO and wild-type mice were injected with GRe (10 mg/kg, i.p.) twice a day for 5 d. A single dose of DOI (2.5 mg/kg, i.p.) or saline was administered 2 h after the final treatment with GRe. Additional mice received MDL (3 mg/kg, i.p., 30 min prior to DOI treatment) or rottlerin (3 μg, i.c.v./brain, 6 and 2 h before DOI treatment). The application of GRe, rottlerin, and MDL were based on our previous study [13,35,54]. Serotonergic behaviors and head twitch response were assessed for 30 min post-DOI-treatment. Rectal temperature was measured at 60 min post DOI treatment, and the mice were sacrificed immediately. The brains were dissected, and the hypothalamus was collected instantly, frozen using liquid nitrogen, and stored at −70 °C until analysis. The experimental design is illustrated in Figure 1.

4.4. Serotonergic Behaviors

DOI (2.5 mg/kg, i.p.) was injected after 15 min of acclimatization in a black-painted cage (260 mm × 200 mm × 140 mm). Behaviors linked with rodent serotonin syndrome were recorded in ten (the first experiment) or five (the second experiment) different 1 min time-periods separated by 6-min intervals, starting 5 min post-DOI administration. In each assessment period, the following behaviors were recorded: intermittent behaviors, including forepaw treading, head weaving, backward movement, and forepaw treading (scored on a scale of 0–4; 0 = absent, 1 = present once, 2 = present several times, 3 = present frequently, 4 = present continuously); continuous behaviors, including straub tail, hind limb abduction, low body posture, and tremor (scored on a scale of 0–4; 0 = absent, 1 = perceptible, 2 = weak, 3 = medium, 4 = maximal). Overall serotonergic behavior scores were calculated for each 1 min time-period, and then summed together [35,54,102].

4.5. Head Twitch Response

The number of head twitch responses was measured in ten (the first experiment) or five (the second experiment) different 1 min time-periods separated by 6 min intervals, starting 5 min post-DOI-administration. The number of head twitch responses in each 1 min period is displayed, or the total number of head twitch response summed from all the periods is shown [36].

4.6. Rectal Temperature

Rectal temperature was measured by inserting an oil-lubricated thermometer at least 3 cm into the mouse rectum under ambient temperature (21 ± 1 °C). Mice were gently handled to avoid sudden movements. Animals with an unsuccessful attempt of probe insertion were excluded from the group [35,54].

4.7. Preparation of Cytosolic and Mitochondrial Fraction for Neurochemical and Western Blot Analyses

Hypothalamic tissues were homogenized using ice-cold homogenization buffer comprising 0.5 mM potassium EGTA, 0.25 M sucrose, 10 mM Tris-HCl (pH 7.4), and protease inhibitor cocktail (Sigma-Aldrich) by using a Dounce homogenizer. Homogenates were centrifuged at 2000× g for 10 min, and nuclei and unbroken cells were removed. Further, to obtain crude mitochondrial pellets and cytosolic supernatants, the suspension was centrifuged at 12,000× g for 15 min. Crude mitochondrial pellets were suspended in 3% Ficoll 400 (Sigma-Aldrich) in Ficoll dilution buffer containing 0.1 mM potassium EGTA, 60 mM sucrose, 10 mM Tris-HCl (pH 7.4), and 0.25 M mannitol. A Ficoll density gradient was formed by pouring crude mitochondrial suspension in 3% Ficoll over 6% Ficoll 400 solution. The suspension was centrifuged at 11,500× g for 10 min to obtain purified mitochondrial pellets, further resuspended in a buffer containing protease cocktail (pH 7.4), 210 mM mannitol, 5 mM HEPES, and 70 mM sucrose. For Western blot analysis, 100 μL lysis buffer was added to mitochondrial pellets [103,104].

4.8. Mitochondrial Preparation for the Measurement of Mitochondrial Membrane Potential and Intramitochondrial Ca2+ Level

Sodium pentobarbital (60 mg/kg) was used to anesthetize the animals and then perfused transcardially with ice-cold homogenization buffer (30 mL) comprising 20 mM HEPES, 250 mM sucrose, and 1 mM EDTA, pH 7.2.
The animals were then decapitated, following which the hypothalami (~1 g) were dissected out, rinsed in homogenization buffer (9 mL), and processed in a tissue homogenizer. The homogenate was centrifuged at 1300× g for 10 min, supernatant was removed, and it was centrifuged again at 10,000× g for 10 min. Using a hand-held homogenizer, the pellet was then gently resuspended (four strokes) in 30 mL homogenization buffer and centrifuged at 10,000× g for 10 min, and the resulting pellet was resuspended and rinsed in an homogenization buffer (EDTA-free). All the centrifugation steps were carried out at 4 °C. The mitochondrial pellet was then resuspended at a final concentration of ~20 mg/mL in 250 mM sucrose, and placed on ice. This process was completed within an hour [13,104,105].

4.9. Western Blot Analysis

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 8% or 10% was used to separate proteins (20 μg/lane) and followed by transfer onto polyvinylidene difluoride membranes. Then, blocking of membranes was commenced using 5% non-fat milk for 30 min, followed by overnight incubation with primary antibodies against PKCδ (1:10,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), p-PKCδ at Tyr 311 (1:500; Santa Cruz Biotechnology), COX IV (1:500, Cell Signaling, Danvers, MA, USA), or β-tubulin (1:50,000, Sigma-Aldrich) at 4 °C. They were then incubated with HRP-conjugated secondary anti-rabbit IgG (1:1000, GE Healthcare, Piscataway, NJ, USA) or anti-mouse IgG (1:1000, Sigma-Aldrich) for 2 h. Enhanced chemiluminescence system (ECL Plus®, GE Healthcare, Arlington Heights, IL, USA.) was used to visualize membrane, and relative intensities of the bands were measured using PhotoCapt MW (version 10.01 for Windows; Vilber Lourmat, Marne la Vallée, France). Then, all the Western blots were normalized to the intensity of COX IV (mitochondrial fraction) or β-tubulin (cytosolic fraction) [13,104].

4.10. Measurement of Mitochondrial Transmembrane Potential

5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolycarbocyanine iodide dye (JC-1; Molecular Probes, Eugene, OR, USA) was used to assess mitochondrial transmembrane potential. This dye exists as a green-fluorescent monomer at low membrane potential but reversibly forms red-fluorescent “J-aggregates” at polarized mitochondrial potentials. Briefly, 250 μg aliquots of isolated mitochondrial protein from hypothalamic tissues were suspended in respiration buffer comprising 20 mM HEPES, 2.5 mM inorganic phosphates (pH 7.2), 250 mM sucrose, 2 mM MgCl2, and 10 mM succinate (5 mM glutamate and 2.5 mM maleate gave similar results in all paradigms) in a final volume of 200 μL. The energized mitochondria were then incubated with 10 μM JC-1 for 30 min at 37 °C, and fluorescence was measured using a fluorescence plate reader (Molecular Devices Inc., Sunnyvale, CA, USA). Mitochondrial polarization was measured by taking the emission ratio from 590 nm to 535 nm with excitation at 490 nm [13,105,106,107,108].

4.11. Measurement of Intramitochondrial Ca2+ Levels

Mitochondrial fractions (250 μg) were incubated at 37 °C with Rhod-2-AM (5 μM; Molecular Probes) for 1 h, followed by washing with Ca2+-free Locke’s solution (3–4 times). This reduced form of Rhod-2-AM is a colorless, non-fluorescent dye with a net positive charge, which promotes sequestration into the mitochondria, whereas dye oxidized in the mitochondria and cleaved AM ester are trapped inside the mitochondria. Fluorescence plate reader (Molecular Devices Inc.) was used to measure fluorescence with an excitation wavelength of 549 nm and emission wavelengths of 581 nm [13,108,109,110].

4.12. Measurement of Complex I Activity

Isolated mitochondrial samples were added to a reaction mixture comprising 3.5 mg/mL bovine serum albumin, 25 mM potassium phosphate buffer (pH 7.8), 1 μM antimycin A, 70 μM decylubiquinone, and 60 μM 2,6-dichloroindophenol, and the reaction mixture was incubated at 37 °C for 3 min. NADH (0.2 mM) was added, and absorbance was measured at 600 nm for 4 min at intervals of 60 s using a microplate reader (Spectra Max Plus 384, Molecular Devices Inc., Sunnyvale, CA, USA). Rotenone (1 μM) was then added, and the absorbance was measured again at 600 nm for 4 min at intervals of 60 s. One unit of complex I activity is defined as 1 μmoL 2,6-dichloroindophenol reduced per minute, and it was calculated based on the extinction coefficient for 2,6-dichloroindophenol (19.1 mM−1 cm−1). The results have been expressed as a percentage of the control group [10,108,111].

4.13. Measurement of Mitochondrial Complex II Activity

Reaction mixtures contained 2 mM EDTA, 80 mM potassium phosphate buffer (pH 7.8), 80 μM 2,6-dichloroindophenol, 1 mg/mL bovine serum albumin, 50 μM decylubiquinone, 3 μM rotenone, and 1 μM antimycin A. These were incubated for 10 min at 37 °C. Potassium cyanide (KCN) (0.3 mM) and succinate (10 mM) were added to start the reaction. Absorbance at 600 nm was recorded at 37 °C for 5 min at intervals of 1 min, using a microplate reader (Spectra Max Plus 384, Molecular Devices Inc., Sunnyvale, CA, USA). One unit of complex II activity is defined as the reduction of 1 μmol 2,6-dichloroindophenol per minute. Calculation of activity was based on the extinction coefficient of 2,6-dichloroindophenol (19.1 mM−1 cm−1) [10,108,111].

4.14. Determination of ROS

Cytosolic and mitochondrial fractions were incubated with 5 μM 2′,7′-dichlorofluorescein diacetate (DCFH-DA, Molecular Probes) for 15 min at 37 °C. The fluorescence intensity was measured at an excitation and emission wavelength of 488 nm and 528 nm, respectively, using a fluorescence microplate reader (Molecular Devices Inc.) [104,112].

4.15. Determination of HNE

OxiSelectTM HNE adduct ELISA kit (Cell Biolabs, Inc., San Diego, CA, USA) was used to determine the quantity of lipid peroxidation by assessing the level of 4-hydroxynonenal (HNE), according to the manufacturer’s instruction. Cytosolic and mitochondrial fractions (100 μL) at a protein concentration of 10 μg/mL were incubated in a 96-well protein binding plate at 4 °C overnight. HNE adducts in each well were labeled with HNE antibody after the protein adsorption, followed by HRP-conjugated secondary antibody. Substrate solution was then added to perform colorimetric development. Absorbance was recorded at 450 nm using a microplate reader (Molecular Devices Inc.), and the standard curve of HNE-BSA was used to calculate the amount of HNE adduct in each sample.

4.16. Determination of Protein Carbonyl

Protein oxidation was determined by analyzing the content of protein carbonyl groups using a 2,4-dinitrophenylhydrazine (DNPH)-labeling procedure [113]. DNPH-labeled protein was detected using a microplate reader [10,13,104,108], and the results were represented as nmol of DNPH incorporated/mg protein based on the extinction coefficient for aliphatic hydrazones (21 mM−1 cm−1). BCA Protein Assay kit (Thermo Scientific) was used to measure protein concentration.

4.17. Determination of SOD

The reaction mixture containing 30 μM cytochrome c, 70 mM potassium phosphate buffer (pH 7.8), 150 μM xanthine, and cytosolic or mitochondrial preparations in phosphate buffer was diluted 10-fold with PBS to a final volume of 3 mL. The reaction was initiated by adding 50 units xanthine oxidase (10 μL), and absorbance was measured at 550 nm by microplate reader (Molecular Devices Inc.). One unit of SOD is defined as the quantity required to inhibit the rate of cytochrome c reduction by 50%. Total SOD was measured by adding KCN (10 μM) to the medium to inhibit cytochrome oxidase activity. To estimate mitochondrial Mn-SOD activity, Cu, Zn-SOD activity was abolished by adding KCN (1 mM) to the mixture. Cu, Zn-SOD activity was calculated by deducting the Mn-SOD activity from the total SOD activity [10,13].

4.18. Determination of GPx

The incubation mixtures contained 0.2 mM NADPH, 2 mM reduced glutathione, and 1.4 IU glutathione reductase in 0.05 M potassium phosphate buffer, pH 7.0. Reactions were initiated by simultaneous addition of cytosolic or mitochondrial fractions (0.3–0.8 mg protein) and 0.25 mM cumene hydroperoxide. Microplate reader (Molecular Devices Inc.) was used to measure absorbance at 340 nm at room temperature. The reaction rate at 340 nm was determined using the NADPH extinction coefficient (6.22 mM−1 cm−1), and GPx activity was expressed as nmol NADPH oxidized per minute per milligram protein at 25 °C [10,13,114].

4.19. Statistical Analyses

In the present study, data analysis was accomplished by one-way analysis of variance (ANOVA) with post-hoc Fisher’s least significant difference (LSD) pairwise comparison tests using IBM SPSS ver. 24.0 (IBM Corp., Armonk, NY, USA). Temporal changes in serotonergic behaviors, head twitch response, and rectal temperature were analyzed using two-way ANOVA with post-hoc Fisher’s LSD pairwise comparison tests, and p-values < 0.05 reflected statistical significance.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ijms22137219/s1, Figure S1. Western blot data of Figure 2 in main text. Figure S2. Effect of GRe or 5-HT2A receptor antagonist MDL on the DOI-induced serotonergic behaviors: head weaving (A), forepaw treading (B), hind-limb abduction (C), straub tail (D), tremor (E), and low body posture (F) in wild-type and PKCδ KO mice. Supplementary Figure S3. Effect of GRe, rottlerin, or MDL alone on overall serotonergic behavioral score (A), head twitch response (B), and rectal temperature (C) in wild-type and PKCδ KO mice.

Author Contributions

Conceptualization, E.-J.S., J.H.J., S.K.K. and H.-C.K.; methodology, E.-J.S., B.-T.N., N.S., S.K.K. and H.-C.K.; software, N.S., E.-J.S. and Y.H.C.; validation, E.-J.S. and J.H.J.; investigation and visualization, J.K.B., S.-Y.N., Y.H.C. and Y.L.; data curation, B.-T.N., N.S., E.-J.S. and T.N.; writing—original draft preparation, H.-C.K.; writing—review and editing, E.-J.S. and H.-C.K.; supervision, E.-J.S., J.H.J., S.K.K., T.N. and H.-C.K.; funding acquisition, H.-C.K. and Y.L.; formal analysis, H.-C.K. and S.K.K. All authors have read and agreed to the published version of the manuscript.

Funding

This study was performed with the support of the R&D Program for Forest Science Technology (Project No. 2020203C10-2122-BA01) provided by Korea Forest Service (Korea Forestry Promotion Institute), and with the support of research grant #19182MFDS410 from Korea Food and Drug Administration, Republic of Korea.

Institutional Review Board Statement

All experiments in this study involving animals’ treatment were performed in strict accordance with the National Institutes of Health (NIH) Guide for the Humane Care and Use of Laboratory Animals (NIH Publication No.85–23, 1985; grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdfwww.dels.nas.edu/ila; August 2019). The present study was carried out according to the Institute for Laboratory Research (ILAR) Guidelines for the Care and Use of Laboratory Animals.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no conflict interests.

References

  1. Lü, J.M.; Yao, Q.; Chen, C. Ginseng compounds: An update on their molecular mechanisms and medical applications. Curr. Vasc. Pharmacol. 2009, 7, 293–302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Christensen, L.P. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv. Food Nutr. Res. 2009, 55, 1–99. [Google Scholar] [CrossRef]
  3. Attele, A.S.; Wu, J.A.; Yuan, C.S. Ginseng pharmacology: Multiple constituents and multiple actions. Biochem. Pharmacol. 1999, 58, 1685–1693. [Google Scholar] [CrossRef]
  4. Ko, S.K.; Bae, H.M.; Cho, O.S.; Im, B.O.; Chung, S.H.; Lee, B.Y. Analysis of ginsenoside composition of ginseng berry and seed. Food Sci. Biotechnol. 2008, 17, 1379–1382. [Google Scholar]
  5. Ko, S.K.; Cho, O.S.; Bae, H.M.; Im, B.O.; Lee, O.H.; Lee, B.Y. Quantitative analysis of ginsenosides composition in flower buds of various ginseng plants. J. Korean Soc. Appl. Biol. Chem. 2011, 54, 154–157. [Google Scholar] [CrossRef]
  6. Joo, K.M.; Lee, J.H.; Jeon, H.Y.; Park, C.W.; Hong, D.K.; Jeong, H.J.; Lee, S.J.; Lee, S.Y.; Lim, K.M. Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/mass spectrometric method. J. Pharm. Biomed. Anal. 2010, 51, 278–283. [Google Scholar] [CrossRef] [PubMed]
  7. Xie, J.T.; Shao, Z.H.; Vanden Hoek, T.L.; Chang, W.T.; Li, J.; Mehendale, S.; Wang, C.Z.; Hsu, C.W.; Becker, L.B.; Yin, J.J.; et al. Antioxidant effects of ginsenoside Re in cardiomyocytes. Eur. J. Pharmacol. 2006, 532, 201–207. [Google Scholar] [CrossRef] [PubMed]
  8. Kim, Y.K.; Yoo, D.S.; Xu, H.; Park, N.I.; Kim, H.H.; Choi, J.E.; Park, S.U. Ginsenoside content of berries and roots of three typical Korean ginseng (Panax ginseng) cultivars. Nat. Prod. Commun. 2009, 4, 903–906. [Google Scholar] [CrossRef] [Green Version]
  9. Dang, D.K.; Shin, E.J.; Kim, D.J.; Tran, H.Q.; Jeong, J.H.; Jang, C.G.; Nah, S.Y.; Jeong, J.H.; Byun, J.K.; Ko, S.K.; et al. Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin1 receptor. J. Neuroinflammation 2018, 15, 52. [Google Scholar] [CrossRef]
  10. Tran, T.V.; Shin, E.J.; Dang, D.K.; Ko, S.K.; Jeong, J.H.; Nah, S.Y.; Jang, C.G.; Lee, Y.J.; Toriumi, K.; Nabeshima, T.; et al. Ginsenoside Re protects against phencyclidine-induced behavioral changes and mitochondrial dysfunction via interactive modulation of glutathione peroxidase-1 and NADPH oxidase in the dorsolateral cortex of mice. Food Chem. Toxicol. 2017, 110, 300–315. [Google Scholar] [CrossRef]
  11. Tu, T.T.; Sharma, N.; Shin, E.J.; Tran, H.Q.; Lee, Y.J.; Jeong, J.H.; Jeong, J.H.; Nah, S.Y.; Tran, H.P.; Byun, J.K.; et al. Ginsenoside Re Protects Trimethyltin-Induced Neurotoxicity via Activation of IL-6-Mediated Phosphoinositol 3-Kinase/Akt Signaling in Mice. Neurochem. Res. 2017, 42, 3125–3139. [Google Scholar] [CrossRef] [PubMed]
  12. Nam, Y.; Wie, M.B.; Shin, E.J.; Nguyen, T.T.; Nah, S.Y.; Ko, S.K.; Jeong, J.H.; Jang, C.G.; Kim, H.C. Ginsenoside Re protects methamphetamine-induced mitochondrial burdens and proapoptosis via genetic inhibition of protein kinase C delta in human neuroblastoma dopaminergic SH-SY5Y cell lines. J. Appl. Toxicol. 2015, 35, 927–944. [Google Scholar] [CrossRef] [PubMed]
  13. Shin, E.J.; Shin, S.W.; Nguyen, T.T.; Park, D.H.; Wie, M.B.; Jang, C.G.; Nah, S.Y.; Yang, B.W.; Ko, S.K.; Nabeshima, T.; et al. Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cδ gene. Mol. Neurobiol. 2014, 49, 1400–1421. [Google Scholar] [CrossRef] [PubMed]
  14. Boyer, E.W.; Shannon, M. The serotonin syndrome. N. Engl. J. Med. 2005, 352, 1112–1120. [Google Scholar] [CrossRef] [Green Version]
  15. Birmes, P.; Coppin, D.; Schmitt, L.; Lauque, D. Serotonin syndrome: A brief review. CMAJ 2003, 168, 1439–1442. [Google Scholar]
  16. Ener, R.A.; Meglathery, S.B.; Van Decker, W.A.; Gallagher, R.M. Serotonin syndrome and other serotonergic disorders. Pain Med. 2003, 4, 63–74. [Google Scholar] [CrossRef] [PubMed]
  17. Voizeux, P.; Lewandowski, R.; Daily, T.; Ellouze, O.; Bouchot, O.; Bouhemad, B.; Guinot, P.G. Case of Cardiac Arrest Treated with Extra-Corporeal Life Support after MDMA Intoxication. Case Rep. Crit. Care 2019, 2019, 7825915. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Nadkarni, G.N.; Hoskote, S.S.; Piotrkowski, J.; Annapureddy, N. Serotonin syndrome, disseminated intravascular coagulation, and hepatitis after a single ingestion of MDMA in an Asian woman. Am. J. Ther. 2014, 21, e117–e119. [Google Scholar] [CrossRef] [PubMed]
  19. Davies, O.; Batajoo-Shrestha, B.; Sosa-Popoteur, J.; Olibrice, M. Full recovery after severe serotonin syndrome, severe rhabdomyolysis, multi-organ failure and disseminated intravascular coagulopathy from MDMA. Heart Lung. 2014, 43, 117–119. [Google Scholar] [CrossRef] [PubMed]
  20. Dobry, Y.; Rice, T.; Sher, L. Ecstasy use and serotonin syndrome: A neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors. Int. J. Adolesc. Med. Health 2013, 25, 193–199. [Google Scholar] [CrossRef]
  21. Vuori, E.; Henry, J.A.; Ojanperä, I.; Nieminen, R.; Savolainen, T.; Wahlsten, P.; Jäntti, M. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003, 98, 365–368. [Google Scholar] [CrossRef] [PubMed]
  22. Parrott, A.C. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 2002, 71, 837–844. [Google Scholar] [CrossRef]
  23. Brush, D.E.; Bird, S.B.; Boyer, E.W. Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. J. Toxicol. Clin. Toxicol. 2004, 42, 191–195. [Google Scholar] [CrossRef] [PubMed]
  24. Suzuki, K. Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning. Chudoku Kenkyu 2016, 29, 33–35. [Google Scholar] [PubMed]
  25. Kinoshita, H.; Ohkubo, T.; Yasuda, M.; Yakushiji, F. Serotonin syndrome induced by dextromethorphan (Medicon) administrated at the conventional dose. Geriatr. Gerontol. Int. 2011, 11, 121–122. [Google Scholar] [CrossRef]
  26. Schwartz, A.R.; Pizon, A.F.; Brooks, D.E. Dextromethorphan-induced serotonin syndrome. Clin. Toxicol. 2008, 46, 771–773. [Google Scholar] [CrossRef] [Green Version]
  27. Ganetsky, M.; Babu, K.M.; Boyer, E.W. Serotonin syndrome in dextromethorphan ingestion responsive to propofol therapy. Pediatr. Emerg. Care 2007, 23, 829–831. [Google Scholar] [CrossRef] [PubMed]
  28. Navarro, A.; Perry, C.; Bobo, W.V. A case of serotonin syndrome precipitated by abuse of the anticough remedy dextromethorphan in a bipolar patient treated with fluoxetine and lithium. Gen. Hosp. Psychiatry 2006, 28, 78–80. [Google Scholar] [CrossRef]
  29. Isbister, G.K.; Buckley, N.A. The pathophysiology of serotonin toxicity in animals and humans: Implications for diagnosis and treatment. Clin. Neuropharmacol. 2005, 28, 205–214. [Google Scholar] [CrossRef]
  30. Souza, M.E.; Polizello, A.C.; Uyemura, S.A.; Castro-Silva, O.; Curti, C. Effect of fluoxetine on rat liver mitochondria. Biochem. Pharmacol. 1994, 48, 535–541. [Google Scholar] [CrossRef]
  31. Nahon, E.; Israelson, A.; Abu-Hamad, S.; Varda, S.B. Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death. FEBS Lett. 2005, 579, 5105–5110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Curti, C.; Mingatto, F.E.; Polizello, A.C.; Galastri, L.O.; Uyemura, S.A.; Santos, A.C. Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity. Mol. Cell. Biochem. 1999, 199, 103–109. [Google Scholar] [CrossRef]
  33. Abdel-Razaq, W.; Kendall, D.A.; Bates, T.E. The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem. Res. 2011, 36, 327–338. [Google Scholar] [CrossRef] [PubMed]
  34. Scotton, W.J.; Hill, L.J.; Williams, A.C.; Barnes, N.M. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. Int. J. Tryptophan Res. 2019, 12, 1178646919873925. [Google Scholar] [CrossRef] [Green Version]
  35. Tran, H.Q.; Shin, E.J.; Hoai Nguyen, B.C.; Phan, D.H.; Kang, M.J.; Jang, C.G.; Jeong, J.H.; Nah, S.Y.; Mouri, A.; Saito, K.; et al. 5-HT1A receptor agonist 8-OH-DPAT induces serotonergic behaviors in mice via interaction between PKCδ and p47phox. Food Chem. Toxicol. 2019, 123, 125–141. [Google Scholar] [CrossRef]
  36. Fox, M.A.; French, H.T.; LaPorte, J.L.; Blackler, A.R.; Murphy, D.L. The serotonin 5-HT(2A) receptor agonist TCB-2: A behavioral and neurophysiological analysis. Psychopharmacology 2010, 212, 13–23. [Google Scholar] [CrossRef]
  37. Haberzettl, R.; Fink, H.; Bert, B. Role of 5-HT(1A)- and 5-HT(2A) receptors for the murine model of the serotonin syndrome. J. Pharmacol. Toxicol. Methods 2014, 70, 129–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Takuwa, N.; Ganz, M.; Takuwa, Y.; Sterzel, R.B.; Rasmussen, H. Studies of the mitogenic effect of serotonin in rat renal mesangial cells. Am. J. Physiol. 1989, 257 Pt 2, F431–F439. [Google Scholar] [CrossRef]
  39. Steinberg, S.F. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem. J. 2004, 384 Pt 3, 449–459. [Google Scholar] [CrossRef]
  40. Yoshida, K. PKCdelta signaling: Mechanisms of DNA damage response and apoptosis. Cell Signal. 2007, 19, 892–901. [Google Scholar] [CrossRef] [PubMed]
  41. Shin, E.J.; Duong, C.X.; Nguyen, X.T.; Li, Z.; Bing, G.; Bach, J.H.; Park, D.H.; Nakayama, K.; Ali, S.F.; Kanthasamy, A.G.; et al. Role of oxidative stress in methamphetamine-induced dopaminergic toxicity mediated by protein kinase Cδ. Behav. Brain Res. 2012, 232, 98–113. [Google Scholar] [CrossRef] [Green Version]
  42. Shin, E.J.; Nam, Y.; Tu, T.H.; Lim, Y.K.; Wie, M.B.; Kim, D.J.; Jeong, J.H.; Kim, H.C. Protein kinase Cδ mediates trimethyltin-induced neurotoxicity in mice in vivo via inhibition of glutathione defense mechanism. Arch. Toxicol. 2016, 90, 937–953. [Google Scholar] [CrossRef] [PubMed]
  43. Shin, E.J.; Hwang, Y.G.; Sharma, N.; Tran, H.Q.; Dang, D.K.; Jang, C.G.; Jeong, J.H.; Nah, S.Y.; Nabeshima, T.; Kim, H.C. Role of protein kinase Cδ in dopaminergic neurotoxic events. Food Chem. Toxicol. 2018, 121, 254–261. [Google Scholar] [CrossRef] [PubMed]
  44. Shin, E.J.; Jeong, J.H.; Sharma, G.; Sharma, N.; Kim, D.J.; Pham, D.T.; Trinh, Q.D.; Dang, D.K.; Nah, S.Y.; Bing, G.; et al. Protein kinase Cδ mediates methamphetamine-induced dopaminergic neurotoxicity in mice via activation of microsomal epoxide hydrolase. Food Chem. Toxicol. 2019, 133, 110761. [Google Scholar] [CrossRef] [PubMed]
  45. Shin, E.J.; Dang, D.K.; Hwang, Y.G.; Tran, H.Q.; Sharma, N.; Jeong, J.H.; Jang, C.G.; Nah, S.Y.; Nabeshima, T.; Yoneda, Y.; et al. Significance of protein kinase C in the neuropsychotoxicity induced by methamphetamine-like psychostimulants. Neurochem. Int. 2019, 124, 162–170. [Google Scholar] [CrossRef] [PubMed]
  46. Dang, D.K.; Shin, E.J.; Kim, D.J.; Tran, H.Q.; Jeong, J.H.; Jang, C.G.; Ottersen, O.P.; Nah, S.Y.; Hong, J.S.; Nabeshima, T.; et al. PKCδ-dependent p47phox activation mediates methamphetamine-induced dopaminergic neurotoxicity. Free Radic. Biol. Med. 2018, 115, 318–337. [Google Scholar] [CrossRef]
  47. Mai, H.N.; Sharma, N.; Shin, E.J.; Nguyen, B.T.; Nguyen, P.T.; Jeong, J.H.; Cho, E.H.; Lee, Y.J.; Kim, N.H.; Jang, C.G.; et al. Exposure to far-infrared ray attenuates methamphetamine-induced impairment in recognition memory through inhibition of protein kinase C δ in male mice: Comparison with the antipsychotic clozapine. J. Neurosci. Res. 2018, 96, 1294–1310. [Google Scholar] [CrossRef]
  48. Mai, H.N.; Sharma, N.; Shin, E.J.; Nguyen, B.T.; Nguyen, P.T.; Jeong, J.H.; Jang, C.G.; Cho, E.H.; Nah, S.Y.; Kim, N.H.; et al. Exposure to far-infrared rays attenuates methamphetamine-induced recognition memory impairment via modulation of the muscarinic M1 receptor, Nrf2, and PKC. Neurochem. Int. 2018, 116, 63–76. [Google Scholar] [CrossRef]
  49. Shin, E.J.; Duong, C.X.; Nguyen, X.T.; Bing, G.; Bach, J.H.; Park, D.H.; Nakayama, K.; Ali, S.F.; Kanthasamy, A.G.; Cadet, J.L.; et al. PKCδ inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment. Neurochem. Int. 2011, 59, 39–50. [Google Scholar] [CrossRef] [Green Version]
  50. Kramer, H.K.; Poblete, J.C.; Azmitia, E.C. 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) promotes the translocation of protein kinase C (PKC): Requirement of viable serotonin nerve terminals. Brain Res. 1995, 680, 1–8. [Google Scholar] [CrossRef]
  51. Kramer, H.K.; Poblete, J.C.; Azmitia, E.C. Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter. Neuropsychopharmacology 1997, 17, 117–129. [Google Scholar] [CrossRef]
  52. Wang, Q.; Bubula, N.; Brown, J.; Wang, Y.; Kondev, V.; Vezina, P. PKC phosphorylates residues in the N-terminal of the DA transporter to regulate amphetamine-induced DA efflux. Neurosci. Lett. 2016, 622, 78–82. [Google Scholar] [CrossRef] [Green Version]
  53. Loweth, J.A.; Svoboda, R.; Austin, J.D.; Guillory, A.M.; Vezina, P. The PKC inhibitor Ro31-8220 blocks acute amphetamine-induced dopamine overflow in the nucleus accumbens. Neurosci. Lett. 2009, 455, 88–92. [Google Scholar] [CrossRef] [Green Version]
  54. Tran, H.Q.; Lee, Y.; Shin, E.J.; Jang, C.G.; Jeong, J.H.; Mouri, A.; Saito, K.; Nabeshima, T.; Kim, H.C. PKCδ knockout mice are [rotected from dextromethorphan-induced serotonergic behaviors in mice: Involvements of downregulation of 5-HT1A receptor and upregulation of Nrf2-dependent GSH synthesis. Mol. Neurobiol. 2018, 55, 7802–7821. [Google Scholar] [CrossRef]
  55. Phan, D.H.; Shin, E.J.; Sharma, N.; Hoang Yen, T.P.; Dang, D.K.; Lee, Y.S.; Lee, Y.J.; Nah, S.Y.; Cheong, J.H.; Jeong, J.H.; et al. 5-HT2A receptor-mediated PKCδ phosphorylation is critical for serotonergic impairments induced by p-chloroamphetamine in mice. Food Chem. Toxicol. 2020, 141, 111395. [Google Scholar] [CrossRef]
  56. Capela, J.P.; da Costa Araújo, S.; Costa, V.M.; Ruscher, K.; Fernandes, E.; Bastos Mde, L.; Dirnagl, U.; Meisel, A.; Carvalho, F. The neurotoxicity of hallucinogenic amphetamines in primary cultures of hippocampal neurons. Neurotoxicology 2013, 34, 254–263. [Google Scholar] [CrossRef] [PubMed]
  57. Shin, E.J.; Jeong, J.H.; Kim, A.Y.; Koh, Y.H.; Nah, S.Y.; Kim, W.K.; Ko, K.H.; Kim, H.J.; Wie, M.B.; Kwon, Y.S.; et al. Protection against kainate neurotoxicity by ginsenosides: Attenuation of convulsive behavior, mitochondrial dysfunction, and oxidative stress. J. Neurosci. Res. 2009, 87, 710–722. [Google Scholar] [CrossRef] [PubMed]
  58. Zhou, X.M.; Cao, Y.L.; Dou, D.Q. Protective effect of ginsenoside-Re against cerebral ischemia/reperfusion damage in rats. Biol. Pharm. Bull. 2006, 29, 2502–2505. [Google Scholar] [CrossRef] [Green Version]
  59. González-Burgos, E.; Fernández-Moriano, C.; Lozano, R.; Iglesias, I.; Gómez- Serranillos, M.P. Ginsenosides Rd and Re co-treatments improve rotenone-induced oxidative stress and mitochondrial impairment in SH-SY5Y neuroblastoma cells. Food Chem. Toxicol. 2017, 109 Pt 1, 38–47. [Google Scholar] [CrossRef]
  60. Liu, M.; Bai, X.; Yu, S.; Zhao, W.; Qiao, J.; Liu, Y.; Zhao, D.; Wang, J.; Wang, S. Ginsenoside Re Inhibits ROS/ASK-1 dependent mitochondrial apoptosis pathway and activation of Nrf2-antioxidant response in Beta-amyloid-challenged SH-SY5Y cells. Molecules 2019, 24, 2687. [Google Scholar] [CrossRef] [Green Version]
  61. Halliwell, B. Reactive oxygen species and central nervous system. J. Neurochem. 1992, 59, 1609–1623. [Google Scholar] [CrossRef] [PubMed]
  62. Lismont, C.; Revenco, I.; Frabsen, M. Peroxisomal hydrogen peroxide metabolism and signaling in health and disease. Int. J. Mol. Sci. 2019, 20, 3673. [Google Scholar] [CrossRef] [Green Version]
  63. Sharma, G.; Shin, E.J.; Sharma, N.; Nah, S.Y.; Mai, H.N.; Nguyen, B.T.; Jeong, J.H.; Lei, X.G.; Kim, H.C. Glutathione peroxidase-1 and neuromodulation: Novel potentials of an old enzyme. Food Chem. Toxicol. 2021, 148, 111945. [Google Scholar] [CrossRef]
  64. Chance, B.; Sies, H.; Boveris, A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 1979, 59, 527–605. [Google Scholar] [CrossRef]
  65. Xiong, Y.; Shie, F.S.; Zhang, J.; Lee, C.P.; Ho, Y.S. The protective role of cellular glutathione peroxidase against trauma-induced mitochondrial dysfunction in the mouse brain. J. Stroke Cereb. Dis. 2004, 13, 129–137. [Google Scholar] [CrossRef] [PubMed]
  66. Marí, M.; Morales, A.; Colell, A.; García-Ruiz, C.; Kaplowitz, N.; Fernández-Checa, J.C. Mitochondrial glutathione: Features, regulation and role in disease. Biochim. Biophys. Acta. 2013, 1830, 3317–3328. [Google Scholar] [CrossRef] [Green Version]
  67. Ramamoorthy, S.; Giovanetti, E.; Qian, Y.; Blakely, R.D. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J. Biol. Chem. 1998, 273, 2458–2466. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Anji, A.; Sullivan Hanley, N.R.; Kumari, M.; Hensler, J.G. The role of protein kinase C in the regulation of serotonin-2A receptor expression. J. Neurochem. 2001, 77, 589–597. [Google Scholar] [CrossRef]
  69. Mizutani, K.; Sonoda, S.; Wakita, H. Ritanserin, a serotonin-2 receptor antagonist, inhibits functional recovery after cerebral infarction. Neuroreport 2018, 29, 54–58. [Google Scholar] [CrossRef]
  70. Bhattacharyya, S.; Puri, S.; Miledi, R.; Panicker, M.M. Internalization and recycling of 5-HT2A receptors activated by serotonin and protein kinase C-mediated mechanisms. Proc. Natl. Acad. Sci. USA 2002, 99, 14470–14475. [Google Scholar] [CrossRef] [Green Version]
  71. Bhattacharyya, S.; Raote, I.; Bhattacharya, A.; Miledi, R.; Panicker, M.M. Activation, internalization, and recycling of the serotonin 2A receptor by dopamine. Proc. Natl. Acad. Sci. USA 2006, 103, 15248–15253. [Google Scholar] [CrossRef] [Green Version]
  72. Haberzettl, R.; Bert, B.; Fink, H.; Fox, M.A. Animal models of the serotonin syndrome: A systematic review. Behav. Brain Res. 2013, 256, 328–345. [Google Scholar] [CrossRef] [PubMed]
  73. Nisijima, K.; Yoshino, T.; Yui, K.; Katoh, S. Potent serotonin 5-HT2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001, 890, 23–31. [Google Scholar] [CrossRef]
  74. Shin, E.J.; Koh, Y.H.; Kim, A.Y.; Nah, S.Y.; Jeong, J.H.; Chae, J.S.; Kim, S.C.; Yen, T.P.; Yoon, H.J.; Kim, W.K.; et al. Ginsenosides attenuate kainic acid-induced synaptosomal oxidative stress via stimulation of adenosine A(2A) receptors in rat hippocampus. Behav. Brain Res. 2009, 197, 239–245. [Google Scholar] [CrossRef]
  75. Wu, C.W.; Ping, Y.H.; Yen, J.C.; Chang, C.Y.; Wang, S.F.; Yeh, C.L.; Chi, C.W.; Lee, H.C. Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells during methamphetamine induced apoptosis. Toxicol. Appl. Pharmacol. 2007, 220, 243–251. [Google Scholar] [CrossRef] [PubMed]
  76. Beauvais, G.; Atwell, K.; Jayanthi, S.; Ladenheim, B.; Cadet, J.L. Involvement of dopamine receptors in binge methamphetamine-induced activation of endoplasmic reticulum and mitochondrial stress pathways. PLoS ONE 2011, 6, e28946. [Google Scholar] [CrossRef] [Green Version]
  77. Basu, A.; Pal, D. Two faces of protein kinase Cδ: The contrasting roles of PKCδ in cell survival and cell death. Sci. World J. 2010, 10, 2272–2284. [Google Scholar] [CrossRef] [PubMed]
  78. Lee, C.F.; Chen, Y.C.; Liu, C.Y.; Wei, Y.H. Involvement of protein kinase C delta in the alteration of mitochondrial mass in human cells under oxidative stress. Free Radic. Biol. Med. 2006, 40, 2136–2146. [Google Scholar] [CrossRef] [PubMed]
  79. Kanthasamy, A.G.; Kitazawa, M.; Kanthasamy, A.; Anantharam, V. Role of proteolytic activation of protein kinase Cdelta in oxidative stress-induced apoptosis. Antioxid. Redox Signal. 2003, 5, 609–620. [Google Scholar] [CrossRef]
  80. Handy, D.E.; Lubos, E.; Yang, Y.; Galbraith, J.D.; Kelly, N.; Zhang, Y.Y.; Leopold, J.A.; Loscalzo, J. Glutathione peroxidase-1 regulates mitochondrial function to modulate redox-dependent cellular responses. J. Biol. Chem. 2009, 284, 11913–11921. [Google Scholar] [CrossRef] [Green Version]
  81. Esposito, L.A.; Kokoszka, J.E.; Waymire, K.G.; Cottrell, B.; MacGregor, G.R.; Wallace, D.C. Mitochondrial oxidative stress in mice lacking the glutathione peroxidase-1 gene. Free Radic. Biol. Med. 2000, 28, 754–766. [Google Scholar] [CrossRef] [Green Version]
  82. Nicholls, D.G. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim. Biophys. Acta 2009, 1787, 1416–1424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Garratt, J.C.; Kidd, E.J.; Wright, I.K.; Marsden, C.A. Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist, DOI. Eur. J. Pharmacol. 1991, 199, 349–355. [Google Scholar] [CrossRef]
  84. Kidd, E.J.; Garratt, J.C.; Marsden, C.A. Effects of repeated treatment with 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on the autoregulatory control of dorsal raphe 5-HT neuronal firing and cortical 5-HT release. Eur. J. Pharmacol. 1991, 200, 131–139. [Google Scholar] [CrossRef]
  85. Martín-Ruiz, R.; Puig, M.V.; Celada, P.; Shapiro, D.A.; Roth, B.L.; Mengod, G.; Artigas, F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J. Neurosci. 2001, 21, 9856–9866. [Google Scholar] [CrossRef] [Green Version]
  86. Bortolozzi, A.; Díaz-Mataix, L.; Toth, M.; Celada, P.; Artigas, F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 2007, 191, 745–758. [Google Scholar] [CrossRef] [Green Version]
  87. Bortolozzi, A.; Amargós-Bosch, M.; Adell, A.; Díaz-Mataix, L.; Serrats, J.; Pons, S.; Artigas, F. In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: Effect of antipsychotic drugs. Eur. J. Neurosci. 2003, 18, 1235–1246. [Google Scholar] [CrossRef]
  88. Sanders-Bush, E.; Steranka, L.R. Immediate and long-term effects of p-chloroamphetamine on brain amines. Ann. N. Y. Acad. Sci. 1978, 305, 208–221. [Google Scholar] [CrossRef]
  89. Perry, K.W.; Kostrzewa, R.M.; Fuller, R.W. Persistence of long-lasting serotonin depletion by p-chloroamphetamine in rat brain after 6-hydroxydopamine lesioning of dopamine neurons. Biochem. Pharmacol. 1995, 50, 1305–1307. [Google Scholar] [CrossRef]
  90. Van de Kar, L.D.; Javed, A.; Zhang, Y.; Serres, F.; Raap, D.K.; Gray, T.S. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J. Neurosci. 2001, 21, 3572–3579. [Google Scholar] [CrossRef] [Green Version]
  91. Zhang, Y.; Damjanoska, K.J.; Carrasco, G.A.; Dudas, B.; D’Souza, D.N.; Tetzlaff, J.; Garcia, F.; Hanley, N.R.; Scripathirathan, K.; Petersen, B.R.; et al. Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-) DOI. J. Neurosci. 2002, 22, 9635–9642. [Google Scholar] [CrossRef] [Green Version]
  92. Gudelsky, G.A.; Koenig, J.I.; Meltzer, H.Y. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology 1986, 25, 1307–1313. [Google Scholar] [CrossRef]
  93. Mazzola-Pomietto, P.; Aulakh, C.S.; Wozniak, K.M.; Hill, J.L.; Murphy, D.L. Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology 1995, 117, 193–199. [Google Scholar] [CrossRef]
  94. Hoyer, D.; Hannon, J.P.; Martin, G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 2002, 71, 533–554. [Google Scholar] [CrossRef]
  95. Willins, D.L.; Meltzer, H.Y. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J. Pharmacol. Exp. Ther. 1997, 282, 699–706. [Google Scholar] [PubMed]
  96. González-Maeso, J.; Yuen, T.; Ebersole, B.J.; Wurmbach, E.; Lira, A.; Zhou, M.; Weisstaub, N.; Hen, R.; Gingrich, J.A.; Sealfon, S.C. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J. Neurosci. 2003, 23, 8836–8843. [Google Scholar] [CrossRef] [Green Version]
  97. González-Maeso, J.; Weisstaub, N.V.; Zhou, M.; Chan, P.; Ivic, L.; Ang, R.; Lira, A.; Bradley-Moore, M.; Ge, Y.; Zhou, Q.; et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007, 53, 439–452. [Google Scholar] [CrossRef] [Green Version]
  98. Tran, T.V.; Shin, E.J.; Ko, S.K.; Nam, Y.; Chung, Y.H.; Jeong, J.H.; Jang, C.G.; Nah, S.Y.; Yamada, K.; Nabeshima, T.; et al. Mountain-cultivated ginseng attenuates phencyclidine-induced abnormal behaviors in mice by positive modulation of glutathione in the prefrontal cortex of mice. J. Med. Food 2016, 19, 961–969. [Google Scholar] [CrossRef]
  99. Miyamoto, A.; Nakayama, K.; Imaki, H.; Hirose, S.; Jiang, Y.; Abe, M.; Tsukiyama, T.; Nagahama, H.; Ohno, S.; Hatakeyama, S.; et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature 2002, 416, 865–869. [Google Scholar] [CrossRef]
  100. Yamada, J.; Sugimoto, Y.; Ohkura, M.; Inoue, K.; Shinozuka, K.; Kunitomo, M. Role of 5-HT(2) receptor subtypes in depletion of 5-HT induced by p-chloroamphetamine in the mouse frontal cortex. Brain Res. 2001, 911, 141–145. [Google Scholar] [CrossRef]
  101. Sugimoto, Y.; Ohkura, M.; Inoue, K.; Yamada, J. Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice. Eur. J. Pharmacol. 2001, 430, 265–268. [Google Scholar] [CrossRef]
  102. Fox, M.A.; Jensen, C.L.; Gallagher, P.S.; Murphy, D.L. Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. Neuropharmacology 2007, 53, 643–656. [Google Scholar] [CrossRef] [PubMed]
  103. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Analysis of mitochondrial dysfunction during cell death. Curr. Protoc. Cell Biol. 2003. [Google Scholar] [CrossRef] [PubMed]
  104. Shin, E.J.; Nam, Y.; Lee, J.W.; Nguyen, P.T.; Yoo, J.E.; Tran, T.V.; Jeong, J.H.; Jang, C.G.; Oh, Y.J.; Youdim, M.B.H.; et al. N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced dopaminergic toxicity with guaranteed behavioral safety: Involvement of inhibitions of mitochondrial oxidative burdens and p53 gene-elicited pro-apoptotic change. Mol. Neurobiol. 2016, 53, 6251–6269. [Google Scholar] [CrossRef] [PubMed]
  105. Xiong, Y.; Gu, Q.; Peterson, P.L.; Muizelaar, J.P.; Lee, C.P. Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J. Neurotrauma 1997, 14, 23–34. [Google Scholar] [CrossRef]
  106. Bruce-Keller, A.J.; Geddes, J.W.; Knapp, P.E.; McFall, R.W.; Keller, J.N.; Holtsberg, F.W.; Parthasarathy, S.; Steiner, S.M.; Mattson, M.P. Anti-death properties of TNF against metabolic poisoning: Mitochondrial stabilization by MnSOD. J. Neuroimmunol. 1999, 93, 53–71. [Google Scholar] [CrossRef]
  107. Qu, M.; Zhou, Z.; Xu, S.; Chen, C.; Yu, Z.; Wang, D. Mortalin overexpression attenuates beta-amyloid-induced neurotoxicity in SH-SY5Y cells. Brain Res. 2011, 1368, 336–345. [Google Scholar] [CrossRef]
  108. Tran, H.Q.; Shin, E.J.; Saito, K.; Tran, T.V.; Phan, D.H.; Sharma, N.; Kim, D.W.; Choi, S.Y.; Jeong, J.H.; Jang, C.G.; et al. Indoleamine-2,3-dioxygenase-1 is a molecular target for the protective activity of mood stabilizers against mania-like behavior induced by d-amphetamine. Food Chem. Toxicol. 2020, 136, 110986. [Google Scholar] [CrossRef]
  109. Mattson, M.P.; Keller, J.N.; Begley, J.G. Evidence for synaptic apoptosis. Exp. Neurol. 1998, 153, 35–48. [Google Scholar] [CrossRef]
  110. Xu, S.; Pi, H.; Chen, Y.; Zhang, N.; Guo, P.; Lu, Y.; He, M.; Xie, J.; Zhong, M.; Zhang, Y.; et al. Cadmium induced Drp1-dependent mitochondrial fragmentation by disturbing calcium homeostasis in its hepatotoxicity. Cell Death Dis. 2013, 4, e540. [Google Scholar] [CrossRef] [Green Version]
  111. Janssen, A.J.; Trijbels, F.J.; Sengers, R.C.; Smeitink, J.A.; van den Heuvel, L.P.; Wintjes, L.T.; Stoltenborg-Hogenkamp, B.J.; Rodenburg, R.J. Spectrophotometric assay for complex I of the respiratory chain in tissue samples and cultured fibroblasts. Clin. Chem. 2007, 53, 729–734. [Google Scholar] [CrossRef]
  112. Lebel, C.P.; Bondy, S.C. Sensitive and rapid quantitation of oxygen reactive species formation in rat synaptosomes. Neurochem. Int. 1990, 17, 435–440. [Google Scholar] [CrossRef] [Green Version]
  113. Oliver, C.N.; Ahn, B.W.; Moerman, E.J.; Goldstein, S.; Stadtman, E.R. Age-related changes in oxidized proteins. J. Biol. Chem. 1987, 262, 5488–5491. [Google Scholar] [CrossRef]
  114. Lawrence, R.A.; Burk, R.F. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem. Biophys. Res. Commun. 1976, 71, 952–958. [Google Scholar] [CrossRef]
Ijms 22 07219 g001 550
Figure 1. Schematic representation of experimental protocol for investigating the effect of GRe on the serotonergic behaviors induced by DOI in wild-type and PKCδ KO mice. DOI-induced serotonin syndrome behaviors and head twitch responses were analyzed every 6 min for the first 1 h, and rectal temperature was estimated every 15 min for 2 h (the first 1 h plus the second 1 h) (A). Rottlerin was given (3 µg, i.c.v./brain) 6 h and 2 h before the DOI administration. MDL11939 (3 mg/kg, i.p.) was given 30 min prior to DOI injection (B). GRe (10 mg/kg, i.p.) was injected twice a day at an 8 h interval for 5 consecutive days. DOI was injected 2 h after the final administration of GRe (C). Mice were sacrificed 1 h post-DOI-administration for assessing neurochemical changes (B,C). GRe, ginsenoside Re; DOI, 2,5-dimethoxy-4-iodo-amphetamine.
Figure 1. Schematic representation of experimental protocol for investigating the effect of GRe on the serotonergic behaviors induced by DOI in wild-type and PKCδ KO mice. DOI-induced serotonin syndrome behaviors and head twitch responses were analyzed every 6 min for the first 1 h, and rectal temperature was estimated every 15 min for 2 h (the first 1 h plus the second 1 h) (A). Rottlerin was given (3 µg, i.c.v./brain) 6 h and 2 h before the DOI administration. MDL11939 (3 mg/kg, i.p.) was given 30 min prior to DOI injection (B). GRe (10 mg/kg, i.p.) was injected twice a day at an 8 h interval for 5 consecutive days. DOI was injected 2 h after the final administration of GRe (C). Mice were sacrificed 1 h post-DOI-administration for assessing neurochemical changes (B,C). GRe, ginsenoside Re; DOI, 2,5-dimethoxy-4-iodo-amphetamine.
Ijms 22 07219 g001
Ijms 22 07219 g002 550
Figure 2. Effect of GRe, rottlerin, or MDL on the cytosolic (A) and mitochondrial (B) expression of PKCδ 60 min after the DOI administration in the hypothalamus of wild-type mice. Data are expressed as the mean ± SEM (4–6 animals). DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re. * p < 0.05, ** p < 0.01 vs. saline/saline. # p < 0.05, ## p < 0.01 vs. saline/DOI (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons). For more details refer to Supplementary Figure S1.
Figure 2. Effect of GRe, rottlerin, or MDL on the cytosolic (A) and mitochondrial (B) expression of PKCδ 60 min after the DOI administration in the hypothalamus of wild-type mice. Data are expressed as the mean ± SEM (4–6 animals). DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re. * p < 0.05, ** p < 0.01 vs. saline/saline. # p < 0.05, ## p < 0.01 vs. saline/DOI (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons). For more details refer to Supplementary Figure S1.
Ijms 22 07219 g002
Ijms 22 07219 g003 550
Figure 3. Effect of GRe or MDL on the alterations in mitochondrial membrane potential (A) and intra-mitochondrial Ca2+ level (B) induced by DOI in the hypothalamus of wild-type and PKCδ KO mice. Data are expressed as the mean ± SEM (6 animals/group). DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re; PKCδ KO, PKCδ knockout mice. ** p < 0.01 vs. saline/saline/wild-type. # p < 0.05 vs. saline/DOI/wild-type (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons).
Figure 3. Effect of GRe or MDL on the alterations in mitochondrial membrane potential (A) and intra-mitochondrial Ca2+ level (B) induced by DOI in the hypothalamus of wild-type and PKCδ KO mice. Data are expressed as the mean ± SEM (6 animals/group). DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re; PKCδ KO, PKCδ knockout mice. ** p < 0.01 vs. saline/saline/wild-type. # p < 0.05 vs. saline/DOI/wild-type (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons).
Ijms 22 07219 g003
Ijms 22 07219 g004 550
Figure 4. Effect of GRe or MDL on the changes in mitochondrial complex I (A) and complex II (B) activities caused by DOI in the hypothalamus of wild-type and PKCδ KO mice. Data are expressed as the mean ± SEM (6 animals/group). DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re; PKCδ KO, PKCδ knockout mice. * p < 0.05, ** p < 0.01 vs. saline/saline/wild-type. # p < 0.05 vs. saline/DOI/wild-type (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons).
Figure 4. Effect of GRe or MDL on the changes in mitochondrial complex I (A) and complex II (B) activities caused by DOI in the hypothalamus of wild-type and PKCδ KO mice. Data are expressed as the mean ± SEM (6 animals/group). DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re; PKCδ KO, PKCδ knockout mice. * p < 0.05, ** p < 0.01 vs. saline/saline/wild-type. # p < 0.05 vs. saline/DOI/wild-type (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons).
Ijms 22 07219 g004
Ijms 22 07219 g005a 550Ijms 22 07219 g005b 550
Figure 5. Effect of GRe or MDL on the DOI-induced oxidative stress in the cytosolic (A,C,E) and mitochondrial (B,D,F) fractions in the hypothalamus of wild-type and PKCδ KO mice. DOI-induced oxidative stress was assessed by ROS (A,B), 4-HNE (C,D), and protein carbonyl (E,F) levels. DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re; PKCδ KO, PKCδ knockout mice. Data are expressed as the mean ± SEM (6 animals/group). * p < 0.05, ** p < 0.01 vs. saline/saline/wild-type. # p < 0.05, ## p < 0.01 vs. saline/DOI/wild-type (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons).
Figure 5. Effect of GRe or MDL on the DOI-induced oxidative stress in the cytosolic (A,C,E) and mitochondrial (B,D,F) fractions in the hypothalamus of wild-type and PKCδ KO mice. DOI-induced oxidative stress was assessed by ROS (A,B), 4-HNE (C,D), and protein carbonyl (E,F) levels. DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re; PKCδ KO, PKCδ knockout mice. Data are expressed as the mean ± SEM (6 animals/group). * p < 0.05, ** p < 0.01 vs. saline/saline/wild-type. # p < 0.05, ## p < 0.01 vs. saline/DOI/wild-type (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons).
Ijms 22 07219 g005aIjms 22 07219 g005b
Ijms 22 07219 g006 550
Figure 6. Effect of GRe or MDL on the changes in the activities of cytosolic Cu, Zn-SOD (SOD-1; (A)), mitochondrial Mn-SOD (SOD-2; (B)), cytosolic GPx (C), and mitochondrial GPx (D) induced by DOI in the hypothalamus of wild-type and PKCδ KO mice. DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re; PKCδ KO, PKCδ knockout mice. Data are expressed as the mean ± SEM (6 animals/group). * p < 0.05, ** p < 0.01 vs. saline/saline/wild-type. # p < 0.05, ## p < 0.01 vs. saline/DOI/wild-type (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons).
Figure 6. Effect of GRe or MDL on the changes in the activities of cytosolic Cu, Zn-SOD (SOD-1; (A)), mitochondrial Mn-SOD (SOD-2; (B)), cytosolic GPx (C), and mitochondrial GPx (D) induced by DOI in the hypothalamus of wild-type and PKCδ KO mice. DOI, 2,5-dimethoxy-4-iodo-amphetamine; MDL, MDL11939; GRe, ginsenoside Re; PKCδ KO, PKCδ knockout mice. Data are expressed as the mean ± SEM (6 animals/group). * p < 0.05, ** p < 0.01 vs. saline/saline/wild-type. # p < 0.05, ## p < 0.01 vs. saline/DOI/wild-type (one-way ANOVA was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons).
Ijms 22 07219 g006
Ijms 22 07219 g007a 550Ijms 22 07219 g007b 550
Figure 7. Effect of GRe or MDL on DOI-induced overall serotonergic behavioral score, head twitch response, and changes in rectal temperature in wild-type and PKCδ KO mice. Time course of changes in overall serotonergic behavioral score (A). Effect of GRe or MDL on DOI-induced serotonergic behavior within the first 30 min (B). Time course of changes in head twitch response (C). Effect of GRe or MDL on DOI-induced head twitch response within the first 30 min (D). Time course of changes in rectal temperature (E). Effect of GRe or MDL on hyperthermia 60 min post-DOI. Data are expressed as the mean ± SEM (6 animals/group). GRe, ginsenoside Re; MDL, MDL11939; DOI, 2,5-dimethoxy-4-iodo-amphetamine; PKCδ KO, PKCδ knockout mice. ** p < 0.01 vs. saline/saline/wild-type. § p < 0.01 vs. saline/saline/wild-type. # p < 0.05 vs. DOI/wild-type or saline/DOI/wild-type. Two-way ANOVA (A,C,E) or one-way ANOVA (B,D,F) was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons. For more details refer to Supplementary Figure S2.
Figure 7. Effect of GRe or MDL on DOI-induced overall serotonergic behavioral score, head twitch response, and changes in rectal temperature in wild-type and PKCδ KO mice. Time course of changes in overall serotonergic behavioral score (A). Effect of GRe or MDL on DOI-induced serotonergic behavior within the first 30 min (B). Time course of changes in head twitch response (C). Effect of GRe or MDL on DOI-induced head twitch response within the first 30 min (D). Time course of changes in rectal temperature (E). Effect of GRe or MDL on hyperthermia 60 min post-DOI. Data are expressed as the mean ± SEM (6 animals/group). GRe, ginsenoside Re; MDL, MDL11939; DOI, 2,5-dimethoxy-4-iodo-amphetamine; PKCδ KO, PKCδ knockout mice. ** p < 0.01 vs. saline/saline/wild-type. § p < 0.01 vs. saline/saline/wild-type. # p < 0.05 vs. DOI/wild-type or saline/DOI/wild-type. Two-way ANOVA (A,C,E) or one-way ANOVA (B,D,F) was performed for statistical analysis followed by Fisher’s LSD pairwise comparisons. For more details refer to Supplementary Figure S2.
Ijms 22 07219 g007aIjms 22 07219 g007b
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Shin, E.-J.; Jeong, J.H.; Nguyen, B.-T.; Sharma, N.; Nah, S.-Y.; Chung, Y.H.; Lee, Y.; Byun, J.K.; Nabeshima, T.; Ko, S.K.; et al. Ginsenoside Re Protects against Serotonergic Behaviors Evoked by 2,5-Dimethoxy-4-iodo-amphetamine in Mice via Inhibition of PKCδ-Mediated Mitochondrial Dysfunction. Int. J. Mol. Sci. 2021, 22, 7219. https://doi.org/10.3390/ijms22137219

AMA Style

Shin E-J, Jeong JH, Nguyen B-T, Sharma N, Nah S-Y, Chung YH, Lee Y, Byun JK, Nabeshima T, Ko SK, et al. Ginsenoside Re Protects against Serotonergic Behaviors Evoked by 2,5-Dimethoxy-4-iodo-amphetamine in Mice via Inhibition of PKCδ-Mediated Mitochondrial Dysfunction. International Journal of Molecular Sciences. 2021; 22(13):7219. https://doi.org/10.3390/ijms22137219

Chicago/Turabian Style

Shin, Eun-Joo, Ji Hoon Jeong, Bao-Trong Nguyen, Naveen Sharma, Seung-Yeol Nah, Yoon Hee Chung, Yi Lee, Jae Kyung Byun, Toshitaka Nabeshima, Sung Kwon Ko, and et al. 2021. "Ginsenoside Re Protects against Serotonergic Behaviors Evoked by 2,5-Dimethoxy-4-iodo-amphetamine in Mice via Inhibition of PKCδ-Mediated Mitochondrial Dysfunction" International Journal of Molecular Sciences 22, no. 13: 7219. https://doi.org/10.3390/ijms22137219

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop